Alnylam Pharmaceuticals | ALNY - Assets

Stock Price
305.54
Daily Change
-8.25 -2.63%
Monthly
-7.05%
Yearly
21.46%
Q2 Forecast
299.00

Alnylam Pharmaceuticals reported $4.97B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Tectonic Therapeutic USD 261.04M 15.96M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025